aphranel® Celebrates First Anniversary With EU MDR Certification, Arc® Launch, and Global Expansion Initiatives
SHANGHAI, China — On May 20, 2026, aphranel® celebrated its first anniversary at the Waldorf Astoria Shanghai on the Bund, marking a major milestone in the brand’s global journey in regenerative aesthetics.
One year ago, aphranel® officially entered the market following approval as China’s first Class III Calcium Hydroxyapatite (CaHA) Microsphere Injectable Facial Filler. At the time, many questioned how far a Chinese original brand focused not on price competition or short-term marketing, but on long-term science and regenerative biomaterials, could truly go.
One year later, aphranel® answered with both numbers and milestones.
Today, aphranel® has achieved cumulative sales of nearly 150,000 syringes, expanded across 28 provinces and 94 cities in China, partnered with more than 620 medical clinics, and certified over 700 physicians nationwide.
Behind these numbers lies the trust of doctors, clinics, and patients — as well as the company’s long-term commitment to regenerative biomaterials and clinical responsibility.
At the anniversary ceremony, aphranel® officially announced that it had obtained European Union Medical Device Regulation (EU MDR) certification, becoming one of the first regenerative CaHA injectable products from the Asia-Pacific region to achieve certification directly under the EU MDR framework.
The certification process lasted 2 years and 7 months under the MDR Class III pathway for absorbable implantable medical devices, involving over 6,381 pages of technical documentation and more than 120 internal regulatory meetings.
For aphranel, this milestone represents more than regulatory approval. It reflects a transition from “China standards” toward participation in global standards for regenerative aesthetics.
Launch of aphranel® Arc®
Another major highlight of the ceremony was the official launch of aphranel® Arc®, the brand’s second core product.
The launch was attended by leading experts in plastic surgery, regenerative medicine, biomaterials, and global medical aesthetics from China, Europe, and the Middle East, alongside aphranel® founder Guangming Lin.
As an extension of aphranel’s philosophy of “The Poetics of Time,” Arc® represents a further exploration of structure, contour, and regenerative aesthetics.
Scientific Dialogue at the Core
Academic exchange remained central throughout the event.
A multidisciplinary roundtable forum explored the future of Chinese innovation in global aesthetics, discussing topics ranging from biomaterial technology and clinical applications to institutional operations and the globalization of Chinese medical aesthetics brands.
International experts also shared insights into the evolving regenerative aesthetics market, while researchers presented new findings on the in vivo degradation kinetics and tissue remodeling mechanisms of aphranel® CaHA microspheres.
These discussions reinforced aphranel’s long-term commitment to combining scientific evidence, regenerative biomaterials, and clinical practice.
The Global Launch of The Norns’ Plan
During the ceremony, aphranel® officially launched “The Norns’ Plan,” a global regenerative aesthetics exchange platform inspired by the brand philosophy of “The Poetics of Time.”
Centered around the concepts of communication, exchange, and integration, the initiative aims to promote international medical education, global case-sharing, clinical strategy discussions, collaborative research, and the development of a worldwide mentor system for regenerative aesthetics.
At the same time, aphranel® signed cooperation agreements with medical experts and partners from Europe, the Middle East, and the Asia-Pacific region — marking a shift from global product expansion toward participation in international academic dialogue and industry collaboration.
Beyond Medical Aesthetics
aphranel® also announced a strategic partnership with Langjiu Manor, one of China’s leading premium liquor estates known for its philosophy of “growth through time.”
The collaboration reflects a shared belief between both brands:
that time is not a cost, but a foundation.
Together, they will launch a cross-disciplinary “Journey Through Time” experience integrating aesthetics, culture, craftsmanship, and high-end lifestyle experiences.
From the First Anniversary to the Next Decade
Over the past 12 years, aphranel® has progressed from long-term biomaterial research to China’s first Class III approval for an original CaHA microsphere injectable facial filler, and now to EU MDR certification under one of the world’s strictest medical regulatory systems.
Today, supported by nearly 150,000 syringes, over 620 partner institutions, 700+ certified doctors, the launch of Arc®, and the global launch of The Norns’ Plan, aphranel® enters a new stage of international development.
Looking ahead, the brand will continue expanding into Europe, Latin America, the Middle East, and Southeast Asia — pursuing a long-term vision for regenerative aesthetics rooted in science, structure, and time.
“Being willing to wait is the highest form of brand signal.”
As founder Guangming Lin shared during the ceremony:
“This anniversary is not the end.
It is the beginning of the next chapter of long-termism.”